Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
STXS 
Stereotaxis Inc (STXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: STXS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4.5
1 Year Target Price $4.5
| 2 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -47.69% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 261.73M USD | Price to earnings Ratio - | 1Y Target Price 4.5 |
Price to earnings Ratio - | 1Y Target Price 4.5 | ||
Volume (30-day avg) 4 | Beta 1.51 | 52 Weeks Range 1.54 - 2.96 | Updated Date 08/15/2025 |
52 Weeks Range 1.54 - 2.96 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.07 | Actual -0.05 |
Profitability
Profit Margin -73.43% | Operating Margin (TTM) -45.2% |
Management Effectiveness
Return on Assets (TTM) -35.03% | Return on Equity (TTM) -198.62% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 265783462 | Price to Sales(TTM) 8.23 |
Enterprise Value 265783462 | Price to Sales(TTM) 8.23 | ||
Enterprise Value to Revenue 8.36 | Enterprise Value to EBITDA -10.06 | Shares Outstanding 90250800 | Shares Floating 60586738 |
Shares Outstanding 90250800 | Shares Floating 60586738 | ||
Percent Insiders 29.61 | Percent Institutions 45.63 |
Upturn AI SWOT
Stereotaxis Inc
Company Overview
History and Background
Stereotaxis Inc. was founded in 2000. It pioneered robotic magnetic navigation for minimally invasive surgery, focusing on cardiac arrhythmia treatment. The company has evolved from initial development to commercialization and ongoing innovation in robotic surgery.
Core Business Areas
- Robotic Navigation Systems: Develops and markets robotic magnetic navigation (RMN) systems for use in electrophysiology procedures. These systems enable precise and remote control of catheters within the heart.
- Consumables and Accessories: Provides disposable components, including magnetic ablation catheters and other accessories used with the RMN systems. Revenue is also derived from services and training.
Leadership and Structure
David Fischel serves as Chairman and CEO. The company has a typical corporate structure with departments for R&D, sales, marketing, operations, finance, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Genesis RMN System: The Genesis RMN System is Stereotaxis' flagship product, a robotic system used for navigating cardiac catheters during electrophysiology procedures. Market share is difficult to pinpoint precisely due to the niche market but it competes with manual catheter navigation, and companies with non-robotic offerings. Competitors include Biosense Webster (JNJ), Abbott, and Boston Scientific.
- MAGiC Ablation Catheter: The MAGiC Ablation Catheter is a disposable catheter specifically designed for use with the Genesis RMN System. It enables precise ablation of cardiac tissue to treat arrhythmias. Market share is linked to the Genesis RMN system's adoption. It enhances procedure precision and efficiency. Competitors include Biosense Webster (JNJ), Abbott, and Boston Scientific's ablation catheters.
Market Dynamics
Industry Overview
The electrophysiology market is growing, driven by an aging population and increasing prevalence of cardiac arrhythmias, such as atrial fibrillation. Technological advancements, including robotic surgery, are shaping the industry.
Positioning
Stereotaxis is positioned as a leader in robotic magnetic navigation for cardiac electrophysiology. Its competitive advantage lies in the precision, safety, and efficiency offered by its RMN systems. However, the higher initial cost can be a hurdle.
Total Addressable Market (TAM)
The electrophysiology market is estimated to be billions of dollars annually. Stereotaxis is targeting a specific niche within this market, focusing on robotic navigation. The TAM is dependent on hospital adoption and reimbursement rates.
Upturn SWOT Analysis
Strengths
- Proprietary robotic magnetic navigation technology
- Enhanced precision and safety compared to manual procedures
- Potential for reduced radiation exposure for physicians
- Strong intellectual property portfolio
Weaknesses
- High initial cost of RMN systems
- Limited installed base compared to established competitors
- Dependence on a relatively small number of key products
- Long sales cycles
Opportunities
- Expanding into new electrophysiology applications
- Developing partnerships with leading hospitals and physicians
- Geographic expansion into emerging markets
- Growing awareness of the benefits of robotic surgery
Threats
- Competition from established players with broader product portfolios
- Technological advancements that could render RMN systems obsolete
- Changes in reimbursement policies that could reduce demand
- Regulatory hurdles for new products and applications
Competitors and Market Share
Key Competitors
- JNJ
- ABT
- BSX
Competitive Landscape
Stereotaxis competes with larger, established medical device companies. Its advantage lies in its specialized robotic technology, but it faces challenges in terms of market penetration and brand recognition.
Growth Trajectory and Initiatives
Historical Growth: Growth has been moderate, driven by increased adoption of RMN systems. However, profitability remains a challenge.
Future Projections: Analysts project continued revenue growth, driven by increasing demand for minimally invasive cardiac procedures. Profitability improvements are crucial.
Recent Initiatives: Recent initiatives include expanding the Genesis RMN system capabilities and partnering with hospitals to demonstrate the clinical and economic benefits of robotic surgery.
Summary
Stereotaxis has innovative robotic technology for cardiac procedures. While it offers precision, its high cost and limited installed base pose challenges. Increased market adoption and improved financials are critical for its long-term success. The company needs to navigate intense competition and potential shifts in reimbursement policies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports (estimates)
- Industry Publications
Disclaimers:
This analysis is based on available information and estimates. Actual results may vary. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stereotaxis Inc
Exchange NYSE MKT | Headquaters Saint Louis, MO, United States | ||
IPO Launch date 2004-08-12 | CEO & Chairman Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 139 | Website https://www.stereotaxis.com |
Full time employees 139 | Website https://www.stereotaxis.com | ||
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as the Genesis RMN, which enable physicians to complete interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN, which is designed to enhance the accessibility of RMN by eliminating the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; V-CAS; and MAGiC catheter for cardiac ablation procedures. Further, it provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.